Barclays PLC Akero Therapeutics, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 70,681 shares of AKRO stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,681
Previous 246,274
71.3%
Holding current value
$1.33 Million
Previous $5.75 Million
68.96%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding AKRO
# of Institutions
193Shares Held
74.2MCall Options Held
429KPut Options Held
591K-
Janus Henderson Group PLC London, X06.12MShares$115 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$102 Million2.2% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$98.5 Million3.09% of portfolio
-
Wellington Management Group LLP Boston, MA5.21MShares$98.1 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$92.1 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $874M
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...